TASLY announced that the drug registration application for Loquat Lung Cleansing Granules submitted in January 2024 has been approved for withdrawal by the National Medical Products Administration. The drug requires further improvement of the application materials, and the company has decided to voluntarily withdraw this drug registration application, planning to resubmit after completing supplementary research. As of the announcement date, the company's cumulative R&D investment in this project amounts to 11.3662 million yuan. This withdrawal will not have a significant impact on the company's current and future production operations and performance
